987例化疗药物相关骨髓抑制药品不良反应报告分析

Analysis of 987 reports of adverse reactions to chemotherapy drug-related myelosuppression

目的了解我院化疗药物相关骨髓抑制的药品不良反应(ADR)发生情况及特点,为临床安全合理使用化疗药物提供参考。方法共收集到2018年1月~2023年6月我院化疗药物所致骨髓抑制的药品不良反应报告987例,对患者年龄、性别、主要诊断肿瘤类型、骨髓抑制分级、骨髓抑制发生时间、化疗药品种类、骨髓抑制主要表现等方面进行分析。结果987例骨髓抑制患者老年患者居多;平均出现骨髓抑制时间为4.85 d,严重(Ⅲ、Ⅳ级)骨髓抑制患者占比8.21%;骨髓抑制主要表现形式为白细胞减少,植物来源及其衍生物类药物导致严重骨髓抑制占比较高。结论临床药师需重视化疗药物导致的骨髓抑制的发生,加强化疗药物用药监护,结合指南等文献提供个性化用药建议,为临床安全合理用药提供参考依据。

Objective To understand the occurrence and characteristics of adverse drug reactions(ADRs)of chemotherapy drug-related myelosuppression in our hospital,and to provide a reference for the safe and rational use of chemotherapy drugs in clinical practice.Methods A total of 987 reports of ADRs related to myelosuppression due to chemotherapy drugs in our hospital were collected from January 2018 to June 2023,and the patients were analyzed in terms of age,gender,main diagnostic tumor type,grading of myelosuppression,time of myelosuppression occurrence,chemotherapy drug type,and main manifestations of myelosuppression.Results The majority of the 987 patients with myelosuppression were elderly patients.The average occurence time of myelosuppression was 4.85 days,and 8.21%of patients with severe(gradeⅢandⅥ)myelosuppression.Leucopenia was the main manifestation of myelosuppression,and plant origin and their derivatives leaded to a high proportion of severe manifestation.Conclusion Clinical pharmacists need to pay attention to the occurrence of myelosuppression caused by chemotherapeutic drugs,strengthen the supervision of chemotherapeutic drug administration,provide personalized medication advice in combination with guidelines and other literature,and provide a reference basis for safe and rational clinical use.